Zhong-Zhe Lin

Dr. Zhong-Zhe Lin


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZLZhong-Zhe Lin
Zhong-Zhe Lin
YJYung-Ming Jeng
Yung-Ming Jeng
FHFu-Chang Hu
Fu-Chang Hu
HPHung-Wei Pan
Hung-Wei Pan
HTHsin-Wei Tsao
Hsin-Wei Tsao
HHHey-Chi Hsu
Hey-Chi Hsu
Background: To investigate the significance of Aurora B expression in hepatocellular carcinoma (HCC). Methods: The Aurora B and Aurora A mRNA level was measured in 160 HCCs and the paired nontumorous liver tissues by reverse transcription-polymerase chain reaction. Mutations of the p53 and β-catenin genes were analyzed in 134 and 150 tumors, respectively, by direct sequencing of exon 2 to exon 11 of p53 and exon 3 of β-catenin. Anticancer effects of AZD1152-HQPA, an Aurora B kinase selective inhibitor, were examined in Huh-7 and Hep3B cell lines. Results: Aurora B was overexpressed in 98 (61%) of 160 HCCs and in all 7 HCC cell lines examined. The overexpression of Aurora B was associated with Aurora A overexpression (P = 0.0003) and p53 mutation (P = 0.002) and was inversely associated with β-catenin mutation (P = 0.002). Aurora B overexpression correlated with worse clinicopathologic characteristics. Multivariate analysis confirmed that Aurora B overexpression was an independent poor prognostic factor, despite its interaction with Aurora A overexpression and mutations of p53 and β-catenin. In Huh-7 and Hep3B cells, AZD1152-HQPA induced proliferation blockade, histone H3 (Ser10) dephosphorylation, cell cycle disturbance, and apoptosis. Conclusion: Aurora B overexpression is an independent molecular marker predicting tumor invasiveness and poor prognosis of HCC. Aurora B kinase selective inhibitors are potential therapeutic agents for HCC treatment.

18 December 2008 in Journal of Hepatology
Verified
Journal Article
Closed access
PDF file
ZLZhong-Zhe Lin
Zhong-Zhe Lin
HHHey-Chi Hsu
Hey-Chi Hsu
CHChih-Hung Hsu
Chih-Hung Hsu
PYPei-Yen Yeh
Pei-Yen Yeh
Chi-Ying F. HuangChi-Ying F. Huang
Chi-Ying F. Huang
LCLi-Tzong Chen
Li-Tzong Chen


11 June 2010 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YSYu-Yun Shao
Yu-Yun Shao
CHChun‐Chieh Huang
Chun‐Chieh Huang
PLPo‐Chin Liang
Po‐Chin Liang
ZLZhong-Zhe Lin
Zhong-Zhe Lin

Verified
Journal Article
Open access
PDF file
CCChen Chen
Chen Chen
TLTsung-Hao Liu
Tsung-Hao Liu
YSYu-Yun Shao
Yu-Yun Shao
KLKao-Lang Liu
Kao-Lang Liu
PLPo-Chin Liang
Po-Chin Liang
ZLZhong-Zhe Lin
Zhong-Zhe Lin
Hepatic artery infusion chemotherapy (HAIC) is a well-established and common treatment for advanced hepatocellular carcinoma (HCC), particularly in East Asia. However, HAIC is not recognized internationally. Although several trials have demonstrated the safety and efficacy of HAIC, evidence corroborating its overall survival (OS) benefits compared with standard treatments is insufficient. Nevertheless, HAIC may provide prominent benefits in selected patients such as patients with portal vein thrombosis or high intrahepatic tumor burden. Moreover, HAIC has been combined with several therapeutic agents and modalities, including interferon-alpha, multikinase inhibitors, radiation therapy, and immunotherapy, to augment its treatment efficacy. Most of these combinations appeared to increase overall response rates compared with HAIC alone, but results regarding OS are inconclusive. Two prospective randomized controlled trials comparing HAIC plus sorafenib with sorafenib alone have reported conflicting results, necessitating further research. As immunotherapy-based combinations became the mainstream treatments for advanced HCC, HAIC plus immunotherapy-based treatments also showed encouraging preliminary results. The trials of HAIC were heterogeneous in terms of patient selection, chemotherapy regimens and doses, HAIC combination agent selections, and HAIC technical protocols. These heterogeneities may contribute to differences in treatment efficacy, thus increasing the difficulty of interpreting trial results. We propose that future trials of HAIC standardize these key factors to reveal the clinical value of HAIC-based treatments for HCC.

1 February 2009 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
YSYing-Chun Shen
Ying-Chun Shen
FHFu-Chang Hu
Fu-Chang Hu
YJYung-Ming Jeng
Yung-Ming Jeng
YCYU-TING CHANG
YU-TING CHANG
ZLZhong-Zhe Lin
Zhong-Zhe Lin
LCLi-Tzong Chen
Li-Tzong Chen
Mitosis dysregulation is common in cancers. This study explored the nuclear expression patterns and prognostic significance of mitotic regulatory proteins, including Aurora kinases, survivin, and p53, in biliary tract cancer (BTC). Archival tumor samples from 161 BTC patients who underwent surgery were tested for the expression of Aurora-A, Aurora-B, survivin, and p53 by immunohistochemistry. The potential endogeneity among the clinicopathologic variables and survival outcome was assessed by a generalized simultaneous equations model. Nuclear overexpression of Aurora-A, Aurora-B, survivin, and p53 was found in 79 (49.1%), 45 (28.0%), 55 (34.2%), and 55 (34.2%) patients, respectively. Intrahepatic cholangiocarcinoma, compared with the other two subtypes, had significantly higher proportions of nuclear overexpression of Aurora-B and survivin (37.8% and 47.3%, respectively). Simultaneous overexpression of Aurora-A and Aurora-B was correlated with that of p53. Overexpression of Aurora-B was also correlated with that of survivin and tumor grade. Our data indicate that simultaneous overexpression of Aurora-A and Aurora-B, suggesting dysregulated mitosis is associated with worse survival in patients with BTC. Independent prognostic factors for poor overall survival included simultaneous overexpression of Aurora-A and Aurora-B (hazard ratio, 1.997; 95% confidence interval, 1.239-3.219; P = 0.0045) and tumor grade (hazard ratio, 2.117; 95% confidence interval, 1.339-3.348; P = 0.0013) assessed by a multivariate analysis stratified by American Joint Committee on Cancer stage and p53 overexpression. Endogeneity testing suggested that nuclear overexpression of p53 and tumor type may influence patient survival through their interactions with Aurora-A/Aurora-B expression and tumor grade. (Cancer Epidemiol Biomarkers Prev 2009;18(2):417–23)